Toni K. Choueiri: CLEAR study biomarker analysis is out
Toni K. Choueiri, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), shared on X:
“CLEAR study biomarker analysis with Robert Motzer and friends is out in Annals of Oncology —thank you EIC Tom Powles for a flawless process!
Lenvatinib + Pembrolizumab improved ORR/PFS vs. sunitinib in aRCC, consistent across PD-L1, gene expression, mutations, subtypes. No predictive biomarker!”
Authors: R.J. Motzer, C. Porta, M. Eto, T.E. Hutson, S.Y. Rha, J.R. Merchan, E. Winquist, H. Gurney, V. Grünwald, S. George, J. Markensohn, J.E. Burgents, R. Cristescu, P. Sachdev, Y. Narita, J. Huang, Z. Zhao, C.E. Okpara, Y. Minoshima, T.K. Choueiri
Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023